Henry Ji, Sorrento CEO (Scilex Pharmaceuticals)
May 19, 2020 11:11 AM EDTUpdated May 20, 07:25 AM
R&D
Coronavirus

How a Cal­i­for­nia biotech briefly tripled its val­ue by hyp­ing a Covid-19 ‘cure’

Jason Mast

Editor

Last week, a Cal­i­for­nia biotech called Sor­ren­to Ther­a­peu­tics emailed re­porters about the dis­cov­ery of an “ex­cep­tion­al­ly po­tent an­ti­body” for Covid-19. Then the CEO, Hen­ry Ji …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times